What is HC Wainwright’s Estimate for OmniAb Q4 Earnings?

OmniAb, Inc. (NASDAQ:OABI) – Research analysts at HC Wainwright issued their Q4 2025 earnings estimates for OmniAb in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s FY2029 earnings at ($0.29) EPS.

OmniAb (NASDAQ:OABI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. During the same quarter last year, the business posted ($0.14) EPS.

Separately, Benchmark dropped their price objective on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a report on Thursday.

OmniAb Trading Up 11.5 %

OmniAb stock opened at $2.53 on Friday. The company has a market capitalization of $357.28 million, a PE ratio of -4.08 and a beta of -0.14. The stock has a 50-day moving average price of $3.34 and a two-hundred day moving average price of $3.77. OmniAb has a 12 month low of $2.23 and a 12 month high of $5.63.

Institutional Investors Weigh In On OmniAb

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in OmniAb by 1.1% in the fourth quarter. Janus Henderson Group PLC now owns 7,960,321 shares of the company’s stock valued at $28,179,000 after buying an additional 88,993 shares during the period. Dimensional Fund Advisors LP raised its position in shares of OmniAb by 4.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company’s stock worth $10,711,000 after acquiring an additional 142,513 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of OmniAb by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,353,442 shares of the company’s stock valued at $8,333,000 after purchasing an additional 28,061 shares during the period. State Street Corp boosted its position in shares of OmniAb by 1.7% during the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after purchasing an additional 34,654 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in OmniAb by 582.1% during the fourth quarter. JPMorgan Chase & Co. now owns 1,001,797 shares of the company’s stock worth $3,546,000 after purchasing an additional 854,929 shares during the period. 72.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other OmniAb news, CFO Kurt A. Gustafson sold 15,526 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $50,304.24. Following the completion of the sale, the chief financial officer now owns 212,720 shares of the company’s stock, valued at approximately $689,212.80. This represents a 6.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John L. Higgins purchased 125,750 shares of the stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $2.35 per share, with a total value of $295,512.50. Following the acquisition, the director now owns 2,762,887 shares in the company, valued at approximately $6,492,784.45. The trade was a 4.77 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 112,260 shares of company stock valued at $376,601. 8.60% of the stock is currently owned by company insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.